Regenxbio Inc [RGNX] stock prices are up 0.27% to $22.39 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The RGNX shares have gain 1.87% over the last week, with a monthly amount glided 18.91%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 11, March 2024, REGENXBIO to Participate in Upcoming Investor Conferences. In a post published today on Yahoo Finance, REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate the following upcoming investor conferences:.
From an analyst’s perspective:
Regenxbio Inc [NASDAQ: RGNX] stock has seen the most recent analyst activity on March 11, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $36. Previously, RBC Capital Mkts upgraded its rating to Outperform on March 08, 2024, and elevated its price target to $35. On March 06, 2024, upgrade upgraded it’s rating to Outperform but maintained its price target of $37 on the stock. Stifel initiated its recommendation with a Buy and recommended $35 as its price target on November 01, 2023. Robert W. Baird started tracking with a Outperform rating for this stock on June 02, 2023, and assigned it a price target of $42. In a note dated June 23, 2022, Berenberg initiated an Buy rating and provided a target price of $61 on this stock.
The stock price of Regenxbio Inc [RGNX] has been fluctuating between $11.83 and $28.80 over the past year. Regenxbio Inc [NASDAQ: RGNX] shares were valued at $22.39 at the most recent close of the market.
Analyzing the RGNX fundamentals
The Regenxbio Inc [NASDAQ:RGNX] reported sales of 90.24M for trailing twelve months, representing a drop of -29.13%. Gross Profit Margin for this corporation currently stands at 0.54% with Operating Profit Margin at -2.97%, Pretax Profit Margin comes in at -2.92%, and Net Profit Margin reading is -2.96%. To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is -0.69 and Total Capital is -0.6. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.29.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.93 points at the first support level, and at 21.48 for the second support level. However, for the 1st resistance point, the stock is sitting at 22.90, and for the 2nd resistance point, it is at 23.42.
Regenxbio Inc [RGNX] reported earnings per share of -$1.43 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.27/share, meaning a difference of -$0.16 and a surprise factor of -12.60%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$1.41 per share as compared to estimates of -$1.52 per share, a difference of $0.11 representing a surprise of 7.20%.
Ratios To Look Out For
It’s worth pointing out that Regenxbio Inc [NASDAQ:RGNX]’s Current Ratio is 2.57. On the other hand, the Quick Ratio is 2.57, and the Cash Ratio is 0.26. Considering the valuation of this stock, the price to sales ratio is 12.16, the price to book ratio is 3.16.
Transactions by insiders
Recent insider trading involved Mills Kenneth T., President and CEO, that happened on Mar 14 ’24 when 15000.0 shares were sold. Chief Medical Officer, PAKOLA STEVE completed a deal on Mar 05 ’24 to sell 12878.0 shares. Meanwhile, President and CEO Mills Kenneth T. sold 15000.0 shares on Feb 14 ’24.
